These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22398900)

  • 1. [Mechanism and therapeutic strategy of second failure of infliximab treatment for Crohn's disease].
    Kanai T; Matsuoka K; Hisamatsu T; Iwao Y; Ogata H; Hibi T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Mar; 109(3):364-9. PubMed ID: 22398900
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adalimumab in Crohn's disease - data from real life].
    López San Román A; Van Domselaar M; Garrido E
    Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
    [No Abstract]   [Full Text] [Related]  

  • 3. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF antibody therapy in Crohn's disease: the risk of a switch.
    Ricart E; Ordás I; Panés J
    Gut; 2012 Feb; 61(2):169-70. PubMed ID: 22068167
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W; Zhu J; Wang L; Lu Y
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 10. Local injection of adalimumab for perianal Crohn's disease: better than infliximab?
    Poggioli G; Laureti S; Pierangeli F; Bazzi P; Coscia M; Gentilini L; Gionchetti P; Rizzello F
    Inflamm Bowel Dis; 2010 Oct; 16(10):1631. PubMed ID: 20848458
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A; Bonnet D; Thebault S; Alric L
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure.
    Echarri A; Castro J; Barreiro M; Carpio D; Pereira S; Lorenzo A
    J Crohns Colitis; 2010 Dec; 4(6):654-60. PubMed ID: 21122576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association and management of Crohn's disease plus hidradenitis suppurativa.
    dos Santos CH; Netto PO; Kawaguchi KY; Parreira Alves JA; de Alencar Souza VP; Reverdito S
    Inflamm Bowel Dis; 2012 Apr; 18(4):E801-2. PubMed ID: 21993924
    [No Abstract]   [Full Text] [Related]  

  • 18. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
    Billioud V; Sandborn WJ; Peyrin-Biroulet L
    Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.